Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors
Article in BMC Cancer (December 2023)
The most recent citing publications are shown below. View all 23 publications that cite this research output on Dimensions.
Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer
Article in Annals of Translational Medicine (October 2021)
Evaluation of kinase-inhibitors nilotinib and everolimus against alveolar echinococcosis in vitro and in a mouse model
Article in Experimental Parasitology (April 2018)